IN2015DN01328A - - Google Patents
Info
- Publication number
- IN2015DN01328A IN2015DN01328A IN1328DEN2015A IN2015DN01328A IN 2015DN01328 A IN2015DN01328 A IN 2015DN01328A IN 1328DEN2015 A IN1328DEN2015 A IN 1328DEN2015A IN 2015DN01328 A IN2015DN01328 A IN 2015DN01328A
- Authority
- IN
- India
- Prior art keywords
- compounds
- present
- therapeutic
- cancer
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702981P | 2012-09-19 | 2012-09-19 | |
| PCT/US2013/060032 WO2014047020A1 (en) | 2012-09-19 | 2013-09-17 | Dihydropyrrolidino-pyrimidines as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01328A true IN2015DN01328A (es) | 2015-07-03 |
Family
ID=49274870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1328DEN2015 IN2015DN01328A (es) | 2012-09-19 | 2013-09-17 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9546173B2 (es) |
| EP (1) | EP2897961B1 (es) |
| JP (1) | JP6186440B2 (es) |
| KR (1) | KR20150056550A (es) |
| CN (1) | CN104640865B (es) |
| AU (1) | AU2013318283A1 (es) |
| BR (1) | BR112015005982A2 (es) |
| CA (1) | CA2882410A1 (es) |
| EA (1) | EA201590600A1 (es) |
| ES (1) | ES2612885T3 (es) |
| IN (1) | IN2015DN01328A (es) |
| MX (1) | MX2015003535A (es) |
| WO (1) | WO2014047020A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9546173B2 (en) * | 2012-09-19 | 2017-01-17 | Novartis Ag | Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors |
| EP3820567A1 (en) | 2018-07-12 | 2021-05-19 | UCB Biopharma SRL | Spirocyclic indane analogues as il-17 modulators |
| WO2020243457A1 (en) * | 2019-05-29 | 2020-12-03 | Viogen Biosciences, Llc | Compounds and therapeutic uses thereof |
| KR20220042184A (ko) * | 2019-08-01 | 2022-04-04 | 프레테고 인코포레이티드 | 최종 당화 산물의 억제제 |
| JP2023505300A (ja) * | 2019-12-10 | 2023-02-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | パラドックス遮断剤としての新規ｂｒａｆ阻害剤 |
| US11718610B2 (en) | 2020-04-30 | 2023-08-08 | Medshine Discovery Inc. | Compounds containing benzosultam |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60330485D1 (de) * | 2002-07-15 | 2010-01-21 | Merck & Co Inc | Zur behandlung von diabetes |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| EP1697375A2 (en) * | 2003-12-02 | 2006-09-06 | Vertex Pharmaceuticals Incorporated | Heterocyclic protein kinase inhibitors and uses thereof |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| AU2005323797B2 (en) | 2005-01-10 | 2009-07-09 | Pfizer Inc. | Pyrrolopyrazoles, potent kinase inhibitors |
| RS51981B (en) | 2005-12-13 | 2012-02-29 | Schering Corporation | POLYCYCLIC INDASOL DERIVATIVES WHICH ARE ERK INHIBITORS |
| BRPI0812450A2 (pt) | 2007-06-05 | 2019-09-24 | Schering Corp | derivados de indazol policíclicos e seu uso como inibidores de erk para o tratamento de câncer |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| US9242981B2 (en) * | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| RU2013126036A (ru) | 2010-11-17 | 2014-12-27 | Ф. Хоффманн-Ля Рош Аг | Способ лечения опухолей |
| MX339873B (es) | 2011-02-28 | 2016-06-15 | Genentech Inc | Inhibidores de serina/treonina cinasa. |
| SG11201405055TA (en) | 2012-03-02 | 2014-09-26 | Genentech Inc | Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives |
| US9546173B2 (en) * | 2012-09-19 | 2017-01-17 | Novartis Ag | Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors |
-
2013
- 2013-09-17 US US14/428,546 patent/US9546173B2/en active Active
- 2013-09-17 KR KR1020157006602A patent/KR20150056550A/ko not_active Application Discontinuation
- 2013-09-17 CA CA2882410A patent/CA2882410A1/en not_active Abandoned
- 2013-09-17 ES ES13771007.5T patent/ES2612885T3/es active Active
- 2013-09-17 EA EA201590600A patent/EA201590600A1/ru unknown
- 2013-09-17 CN CN201380048493.XA patent/CN104640865B/zh active Active
- 2013-09-17 EP EP13771007.5A patent/EP2897961B1/en active Active
- 2013-09-17 JP JP2015533126A patent/JP6186440B2/ja active Active
- 2013-09-17 MX MX2015003535A patent/MX2015003535A/es unknown
- 2013-09-17 BR BR112015005982A patent/BR112015005982A2/pt not_active IP Right Cessation
- 2013-09-17 AU AU2013318283A patent/AU2013318283A1/en not_active Abandoned
- 2013-09-17 IN IN1328DEN2015 patent/IN2015DN01328A/en unknown
- 2013-09-17 WO PCT/US2013/060032 patent/WO2014047020A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013318283A1 (en) | 2015-03-05 |
| EP2897961A1 (en) | 2015-07-29 |
| JP2015529248A (ja) | 2015-10-05 |
| CN104640865B (zh) | 2018-05-11 |
| CA2882410A1 (en) | 2014-03-27 |
| EP2897961B1 (en) | 2016-10-26 |
| EA201590600A1 (ru) | 2015-07-30 |
| CN104640865A (zh) | 2015-05-20 |
| ES2612885T3 (es) | 2017-05-19 |
| US9546173B2 (en) | 2017-01-17 |
| KR20150056550A (ko) | 2015-05-26 |
| US20150274733A1 (en) | 2015-10-01 |
| BR112015005982A2 (pt) | 2017-07-04 |
| JP6186440B2 (ja) | 2017-08-23 |
| WO2014047020A1 (en) | 2014-03-27 |
| MX2015003535A (es) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3366B1 (ar) | مثبطات بيرازوليل كوينوكزالين كاينيز | |
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| EP3603661A3 (en) | Rna containing composition for treatment of tumor diseases | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| PH12015501385A1 (en) | Autotaxin inhibitors | |
| MX2013001970A (es) | Compuestos de pirrolopirimidina y usos de los mismos. | |
| GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| UA111386C2 (uk) | Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ | |
| IN2014MN00986A (es) | ||
| MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
| GB201209613D0 (en) | New compounds | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| JO3438B1 (ar) | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس | |
| UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
| MX343706B (es) | Derivados heterocíclicos novedosos. | |
| PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| IN2015DN01328A (es) | ||
| MX2016004934A (es) | Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
| GEP201606566B (en) | Isoxazolidine derivatives | |
| MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
| MX2017003016A (es) | Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas. |